lirilumab
Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2/3. — Wikipedia
Clinical trial activity
13 trials · 11 clinical orgs · 0 marketing orgs
Earliest trial started Jun 27, 2012 (NCT01592370)
Timeline
Indications
Studied for
- Hodgkin Disease · Phase 1
- Leukemia · Phase 2
- Leukemia, Biphenotypic, Acute · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Lymphoid · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Multiple Myeloma · Phase 1
- Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
KIR2DL2 inhibitor
Blocks the interaction of the three main inhibitory KIR receptors (KIR2DL-1, -2, -3) with their ligands, the human leukocyte antigen-C (HLA-C) molecules.
KIR2DL3 inhibitor
Blocks the interaction of the three main inhibitory KIR receptors (KIR2DL-1, -2, -3) with their ligands, the human leukocyte antigen-C (HLA-C) molecules.
KIR2DL1 inhibitor
Blocks the interaction of the three main inhibitory KIR receptors (KIR2DL-1, -2, -3) with their ligands, the human leukocyte antigen-C (HLA-C) molecules.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLirilumab ↗
- ChEMBLCHEMBL2109500 ↗
Also known as
- anti-kir antibody
- bms-986015
- bms-986015
- bms-986015-01
- iph2102
- iph2102
- lirilumab
- lirilumab
- lirilumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03532451 | Phase 1 | Oct 31, 2018 | Bristol-Myers Squibb, PrECOG, LLC., University of Washington |
| NCT03341936 | Phase 2 | Mar 15, 2018 | Bristol-Myers Squibb, Harvard University |
| NCT03335540 | Phase 1 | Mar 13, 2018 | Bristol-Myers Squibb |
| NCT03347123 | Phase 1/Phase 2 (Phase 2) | Jan 29, 2018 | Incyte |
| NCT03203876 | Phase 1 | Jul 28, 2017 | Bristol-Myers Squibb, Ono Pharmaceuticals |
| NCT02599649 | Phase 2 | Mar 21, 2016 | Bristol-Myers Squibb, University of Texas at Houston |
| NCT02481297 | Phase 2 | Jun 23, 2015 | Bristol-Myers Squibb, University of Texas at Houston |
| NCT02399917 | Phase 2 | Apr 1, 2015 | Bristol-Myers Squibb, University of Texas at Houston |
| NCT02252263 | Phase 1 | Dec 9, 2014 | Bristol-Myers Squibb |
| NCT01750580 | Phase 1 | Dec 1, 2012 | Bristol-Myers Squibb |
| NCT01714739 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2012 | Bristol-Myers Squibb |
| NCT01687387 | Phase 2 | Oct 1, 2012 | ALFA cooperative Group, GOELAMS Cooperative Group, Innate Pharma, Institut Paoli-Calmettes |
| NCT01592370 | Phase 1 | Jun 27, 2012 | Bristol-Myers Squibb |
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 11 | 6 | 2 | 2012 |
| University of Texas at Houston | Academic/Hospital | 3 | 3 | 1 | 2015 |
| ALFA cooperative Group | Academic/Hospital | 1 | 0 | 1 | 2012 |
| GOELAMS Cooperative Group | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Incyte | For profit | 1 | 1 | 1 | 2018 |
| Innate Pharma | For profit | 1 | 1 | 1 | 2012 |
| Institut Paoli-Calmettes | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Ono Pharmaceuticals | For profit | 1 | 0 | 1 | 2017 |
| PrECOG, LLC. | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2018 |